NOT PRECEDENTIAL
UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT _____________
No. 21-2973 _____________
IN RE: AKORN INC.
AFSCME DISTRICT COUNCIL 47 HEALTH & WELFARE FUND; SERGEANTS BENEVOLENT ASSOCIATION HEALTH AND WELFARE FUND, Appellants ______________
APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE (D.C. No. 1-20-cv-01254) District Judge: Honorable Maryellen Noreika ______________
Submitted Under Third Circuit L.A.R. 34.1(a) September 20, 2022
______________
Before: AMBRO, RESTREPO, and FUENTES, Circuit Judges.
(Filed: November 25, 2022) ______________
OPINION* ______________
* This disposition is not an opinion of the full Court and, pursuant to I.O.P. 5.7, does not constitute binding precedent. RESTREPO, Circuit Judge.
This appeal concerns a challenge to the approval of a Chapter 11 bankruptcy plan
(the “Plan”). Appellants are unsecured creditors of Appellee, Akorn, Inc. They raise
several defects in the Plan that they claim left insufficient value to afford their creditor
class a recovery under its waterfall. The Bankruptcy Court approved the Plan and the
District Court affirmed. We will likewise affirm.
I.
We presume the parties’ familiarity with the case and set out only the facts needed
for the discussion below.
The Parties. Appellee Akorn is a pharmaceutical company in the business of
generic and branded health products. Appellants are among plaintiffs to a multidistrict
litigation against Akorn and other generic drug manufacturers for alleged anti-
competitive conduct. In re Generic Pharms. Pricing Antitrust Litig., No. 2:16-MD-2724-
CMR (E.D. Pa. Aug. 5, 2016).
The Merger and Related Pre-Petition Settlement. After a failed merger with
Fresenius Kabi AG in April 2018, Akorn settled related securities litigation with a class
of shareholders in August 2019. In re Akorn, Inc. Data Integrity Secs. Litig., No. 1:18-
CV-1713 (N.D. Ill. Mar. 8, 2018) (the “Class Action Settlement”). Settling plaintiffs,
excluding those who opted out (the “Opt-Out Shareholders”), received a distribution of
2 $27.5 million directly from a D&O insurance carrier and approximately 6.7 million
shares of Akorn common stock.
The Sale. The failed merger and Akorn’s associated financial issues subsequently
affected a loan agreement with Akorn’s secured lenders (the “Secured Lenders”), and a
Standstill Agreement was later reached between the two, allowing Akorn some
“breathing room” to either refinance or pay down its debts. JA385.
The Secured Lenders eventually agreed to serve as a stalking-horse bidder in
Chapter 11, preserving Akorn’s business as a going concern through a “credit bid” on
Akorn’s outstanding debt. JA130. The Secured Lenders subsequently agreed to purchase
the bulk of Akorn’s assets in exchange for a release of Akorn’s debt under the loan
agreement. The Secured Lenders also agreed to assume $5 million of Akorn’s additional
undisputed non-litigation unsecured debt.
Not included in the sale were a remaining D&O insurance policy, hypothetical
avoidance actions to recover the Class Action Settlement, liabilities arising from
litigation against Akorn by Provepharm, and a 50% interest in a defunct nasal spray
product (together, the “Retained Assets”). The Bankruptcy Court approved the sale over
Appellants’ objections, noting that “the market has spoken with respect to the value of
the debtor’s assets,” as “[t]he current offer is the best and only actionable transaction
supported by most parties in interest.” JA589.
The Chapter 11 Plan. Akorn’s reorganization plan included eight classes, with
the Secured Lenders in “Class 3,” and unsecured claimants, like Appellants, in “Class 4.”
Class 3 was designated an “impaired” class, and as such, its approval of the Plan allowed
3 it to proceed, despite objections, as a Bankruptcy Code § 1129(b) “cramdown.” After a
three-day trial, the Bankruptcy Court overruled Appellants’ objections and confirmed the
Plan.
Disposal of the Retained Assets. Each of the remaining Retained Assets was
then strategically disposed of as part of the wind-down process. Post-petition, Akorn
settled with the Opt-Out Shareholders using funds from its remaining D&O insurance
policy, but declined to avoid the Class Action Settlement, citing the cost and uncertainty
of unwinding it. Akorn settled litigation with Provepharm, releasing its counterclaims to
garner Provepharm’s support for the Plan. Similarly, Akorn settled litigation with Rising,
its co-owner in the nasal spray product, in exchange for the rest of its share in the product
and Rising’s support for the Plan.
II.
Appellants raised fifteen errors related to the Plan below; the District Court
rejected all of them. On appeal, Plaintiffs assert that (1) the Retained Assets had value,
and as such, the manner of their distribution under the Plan did not maximize the value of
the estate and violated the absolute priority rule; (2) Akorn should have proceeded
through Chapter 7 instead of Chapter 11; (3) the Plan misclassified creditors and treated
certain classes unfairly; and (4) the Plan was put forth in bad faith.
III.
The District Court had jurisdiction pursuant to 28 U.S.C. § 158(a)(1). We have
jurisdiction pursuant to 28 U.S.C. § 1291.
4 “Because the District Court sat as an appellate court to review the Bankruptcy
Court, we review the Bankruptcy Court’s legal determinations de novo, its factual
findings for clear error, and its exercises of discretion for abuse thereof.” In re Goody's
Family Clothing Inc., 610 F.3d 812, 816 (3d Cir. 2010).1
IV.
We review each of Appellants’ challenges to the Plan in turn.
A. Improper Designation of Retained Assets as Having No Value
Frustrated that they did not recover on their unsecured litigation claims against
Akorn under the Plan, Appellants argue that Akorn’s distribution of the Retained Assets
violated the absolute priority rule and constituted a failure to maximize the value of the
estate available to creditors like themselves.
The absolute priority rule bars transfers of property under a plan to creditors junior
to a claimant class (here an unsecured class), absent the senior class’s consent. 11 U.S.C.
§ 1129(b)(2)(B)(ii). Appellants argue that the Retained Assets were valuable estate
property that should have been used to satisfy their claims and not distributed to junior
creditors. The Bankruptcy Court implicitly and the District Court explicitly rejected this
1 More specifically, the Bankruptcy Court’s findings as to the value of estate property are reviewable for clear error. See In re Fruehauf Trailer Corp., 444 F.3d 203, 214 (3d Cir. 2006). A bankruptcy court’s factual finding “that creditors rejecting the plan would not receive a greater recovery in a Chapter 7 liquidation,” is reviewed for clear error. In re PWS Holding Corp., 228 F.3d, 224, 250 (3d Cir. 2000). Further, this Court “will uphold a plan’s classification scheme so long as it is reasonable and does not arbitrarily designate classes.” In re W.R. Grace & Co.,
Free access — add to your briefcase to read the full text and ask questions with AI
NOT PRECEDENTIAL
UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT _____________
No. 21-2973 _____________
IN RE: AKORN INC.
AFSCME DISTRICT COUNCIL 47 HEALTH & WELFARE FUND; SERGEANTS BENEVOLENT ASSOCIATION HEALTH AND WELFARE FUND, Appellants ______________
APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE (D.C. No. 1-20-cv-01254) District Judge: Honorable Maryellen Noreika ______________
Submitted Under Third Circuit L.A.R. 34.1(a) September 20, 2022
______________
Before: AMBRO, RESTREPO, and FUENTES, Circuit Judges.
(Filed: November 25, 2022) ______________
OPINION* ______________
* This disposition is not an opinion of the full Court and, pursuant to I.O.P. 5.7, does not constitute binding precedent. RESTREPO, Circuit Judge.
This appeal concerns a challenge to the approval of a Chapter 11 bankruptcy plan
(the “Plan”). Appellants are unsecured creditors of Appellee, Akorn, Inc. They raise
several defects in the Plan that they claim left insufficient value to afford their creditor
class a recovery under its waterfall. The Bankruptcy Court approved the Plan and the
District Court affirmed. We will likewise affirm.
I.
We presume the parties’ familiarity with the case and set out only the facts needed
for the discussion below.
The Parties. Appellee Akorn is a pharmaceutical company in the business of
generic and branded health products. Appellants are among plaintiffs to a multidistrict
litigation against Akorn and other generic drug manufacturers for alleged anti-
competitive conduct. In re Generic Pharms. Pricing Antitrust Litig., No. 2:16-MD-2724-
CMR (E.D. Pa. Aug. 5, 2016).
The Merger and Related Pre-Petition Settlement. After a failed merger with
Fresenius Kabi AG in April 2018, Akorn settled related securities litigation with a class
of shareholders in August 2019. In re Akorn, Inc. Data Integrity Secs. Litig., No. 1:18-
CV-1713 (N.D. Ill. Mar. 8, 2018) (the “Class Action Settlement”). Settling plaintiffs,
excluding those who opted out (the “Opt-Out Shareholders”), received a distribution of
2 $27.5 million directly from a D&O insurance carrier and approximately 6.7 million
shares of Akorn common stock.
The Sale. The failed merger and Akorn’s associated financial issues subsequently
affected a loan agreement with Akorn’s secured lenders (the “Secured Lenders”), and a
Standstill Agreement was later reached between the two, allowing Akorn some
“breathing room” to either refinance or pay down its debts. JA385.
The Secured Lenders eventually agreed to serve as a stalking-horse bidder in
Chapter 11, preserving Akorn’s business as a going concern through a “credit bid” on
Akorn’s outstanding debt. JA130. The Secured Lenders subsequently agreed to purchase
the bulk of Akorn’s assets in exchange for a release of Akorn’s debt under the loan
agreement. The Secured Lenders also agreed to assume $5 million of Akorn’s additional
undisputed non-litigation unsecured debt.
Not included in the sale were a remaining D&O insurance policy, hypothetical
avoidance actions to recover the Class Action Settlement, liabilities arising from
litigation against Akorn by Provepharm, and a 50% interest in a defunct nasal spray
product (together, the “Retained Assets”). The Bankruptcy Court approved the sale over
Appellants’ objections, noting that “the market has spoken with respect to the value of
the debtor’s assets,” as “[t]he current offer is the best and only actionable transaction
supported by most parties in interest.” JA589.
The Chapter 11 Plan. Akorn’s reorganization plan included eight classes, with
the Secured Lenders in “Class 3,” and unsecured claimants, like Appellants, in “Class 4.”
Class 3 was designated an “impaired” class, and as such, its approval of the Plan allowed
3 it to proceed, despite objections, as a Bankruptcy Code § 1129(b) “cramdown.” After a
three-day trial, the Bankruptcy Court overruled Appellants’ objections and confirmed the
Plan.
Disposal of the Retained Assets. Each of the remaining Retained Assets was
then strategically disposed of as part of the wind-down process. Post-petition, Akorn
settled with the Opt-Out Shareholders using funds from its remaining D&O insurance
policy, but declined to avoid the Class Action Settlement, citing the cost and uncertainty
of unwinding it. Akorn settled litigation with Provepharm, releasing its counterclaims to
garner Provepharm’s support for the Plan. Similarly, Akorn settled litigation with Rising,
its co-owner in the nasal spray product, in exchange for the rest of its share in the product
and Rising’s support for the Plan.
II.
Appellants raised fifteen errors related to the Plan below; the District Court
rejected all of them. On appeal, Plaintiffs assert that (1) the Retained Assets had value,
and as such, the manner of their distribution under the Plan did not maximize the value of
the estate and violated the absolute priority rule; (2) Akorn should have proceeded
through Chapter 7 instead of Chapter 11; (3) the Plan misclassified creditors and treated
certain classes unfairly; and (4) the Plan was put forth in bad faith.
III.
The District Court had jurisdiction pursuant to 28 U.S.C. § 158(a)(1). We have
jurisdiction pursuant to 28 U.S.C. § 1291.
4 “Because the District Court sat as an appellate court to review the Bankruptcy
Court, we review the Bankruptcy Court’s legal determinations de novo, its factual
findings for clear error, and its exercises of discretion for abuse thereof.” In re Goody's
Family Clothing Inc., 610 F.3d 812, 816 (3d Cir. 2010).1
IV.
We review each of Appellants’ challenges to the Plan in turn.
A. Improper Designation of Retained Assets as Having No Value
Frustrated that they did not recover on their unsecured litigation claims against
Akorn under the Plan, Appellants argue that Akorn’s distribution of the Retained Assets
violated the absolute priority rule and constituted a failure to maximize the value of the
estate available to creditors like themselves.
The absolute priority rule bars transfers of property under a plan to creditors junior
to a claimant class (here an unsecured class), absent the senior class’s consent. 11 U.S.C.
§ 1129(b)(2)(B)(ii). Appellants argue that the Retained Assets were valuable estate
property that should have been used to satisfy their claims and not distributed to junior
creditors. The Bankruptcy Court implicitly and the District Court explicitly rejected this
1 More specifically, the Bankruptcy Court’s findings as to the value of estate property are reviewable for clear error. See In re Fruehauf Trailer Corp., 444 F.3d 203, 214 (3d Cir. 2006). A bankruptcy court’s factual finding “that creditors rejecting the plan would not receive a greater recovery in a Chapter 7 liquidation,” is reviewed for clear error. In re PWS Holding Corp., 228 F.3d, 224, 250 (3d Cir. 2000). Further, this Court “will uphold a plan’s classification scheme so long as it is reasonable and does not arbitrarily designate classes.” In re W.R. Grace & Co., 729 F.3d 311, 326 (3d Cir. 2013) (internal quotations omitted). Finally, we review the Bankruptcy Court’s good-faith determination for abuse of discretion. See In re SGL Carbon Corp., 200 F.3d 154, 159 (3d Cir. 1999). 5 premise, finding that different treatment of the Retained Assets would have yielded no
greater recovery for Appellants or the estate as a whole.
Appellants emphasize that “any otherwise cognizable property interest must be treated as
sufficiently valuable to be recognized under the Bankruptcy Code.” Bank of Am. Nat. Tr.
& Sav. Ass’n v. 203 N. Lasalle St. P’ship, 526 U.S. 434, 455 (1999). However, our Court
has recognized that “value” is not a zero-sum proposition in this context. In In re PWS
Holding Corp., we held that an asset “of only marginal viability [that] could be costly for
the reorganized entity to pursue” may be found to have no value to that entity for
purposes of the absolute priority rule, even if exchanged for value to a third party during
reorganization. 228 F.3d 224, 242 (3d Cir. 2000). The same logic applies to the duty to
maximize the value of the estate. In re Am. Capital Equip., LLC, 688 F.3d 145, 163 (3d
Cir. 2012) (noting no need to pursue asset if cost of pursuit would exceed its value, as
duty to maximize value of the estate looks to net assets).
Appellants argue that the Retained Assets must have been valuable because they
were exchanged for value in the form of support for the Plan, release of litigation claims,
etc. But under our precedents, this is not an improper distribution to junior credit holders
if the value of the assets is contingent or conjectural – like the uncertain and costly-to-
pursue litigation and avoidance claims, nasal spray product requiring a $3 million cash
infusion to be potentially viable, and narrowly construed insurance policy at issue here.
Appellants’ counter-assertions as to the value of the Retained Assets to Akorn are
both highly speculative and unsupported by evidence. Especially considering the more
certain and cost-efficient ways in which Akorn strategically handled those assets while
6 piecing together the precarious puzzle of its restructuring plan, Appellants fail to
convince us that there existed a more fruitful alternate course. The Bankruptcy Court and
District Court’s determinations that each of the Retained Assets was valueless to the
estate were not clearly erroneous, and their findings that the Plan maximized the value of
the estate and did not violate the absolute priority rule were proper.2
B. Retained Assets Should Have Been Liquidated
Appellants also charge that under Bankruptcy Code § 1129(a)(7), the Retained
Assets should have instead been liquidated and distributed under a Chapter 7 liquidation,
as this would have provided them a greater recovery. Appellants’ claim assumes that the
Retained Assets indeed had value, however, as discussed above, they have failed to
persuade that theirs or any creditor class would have captured more or any value from
those assets through liquidation. The Bankruptcy Court credited the analysis of Akorn’s
financial advisor, who concluded that liquidation would have also yielded “zero percent
recovery” to Appellants’ class. JA802. Appellants have provided no counter-analysis or
other compelling reason to doubt that conclusion.
C. Misclassification of Claims and Unfair Treatment of Creditors
2 Appellee argues that certain of Appellants’ claims about the Retained Assets were waived when Appellants only challenged the Plan as a whole, but Appellee itself did not raise this argument before the District Court, and so their waiver argument is thereby waived on appeal. See United States v. Quiroz, 22 F.3d 489, 491 (2d Cir. 1994) (collecting cases).
7 Appellants assert that the Plan treated members of Class 4—the unsecured
creditors—unequally in violation of Bankruptcy Code § 1123(a)(4) because the Secured
Lenders purchased only certain unsecured claims. However, those claims were
purchased before the approval of the Plan and were never even in Class 4. To skirt this
logical flaw, Appellants claim that a statement by the Committee of Unsecured Creditors
that the Secured Lenders would assume “essentially all undisputed non-litigation
unsecured debt” was insufficiently clear to ascertain which claims were to be covered by
the Plan, and, as a result, these claims defaulted into Class 4 until properly identified.
This argument strains reason, particularly as the Bankruptcy Code does not require that
the covered claims be identified on a liability-by-liability basis. 11 U.S.C. § 1123(a)(1).
The Bankruptcy Court’s approval of the Plan’s classification scheme—which never
included the unsecured claims at all—was reasonable and not arbitrary.
Appellants also claim that the Secured Lenders’ class was not “impaired” for
purposes of approving the Plan despite objections as a § 1129(b) “cramdown,” since it
“received everything it was due under the Standstill Agreement.” Appellee Br. at 37–38.
However, “impairment” for these purposes is presumed unless a plan “leaves unaltered
the legal, equitable, and contractual rights to which such claim or interest entitles the
holder of such claim or interest.” 11 U.S.C. § 1124(1); In re PPI Enterprises (U.S.) Inc.,
324 F.3d 197, 202–03 (3d Cir. 2003). The Plan clearly altered the Secured Lenders’
rights, as one of its primary functions was to curtail the Lenders’ contractual remedies
8 under the loan agreement in the event of a default on their loan to Appellee Akorn.3 The
Bankruptcy Court’s impairment determination was not in error.
D. The Plan Was Not Proposed in Good Faith
Lastly, Appellants charge that the Plan was not proposed in good faith, as
required by 11 U.S.C. §1129(a)(3), because it intentionally “singled out unsecured
litigation claimants and froze them out of the distribution of estate value.” Appellant
Br. at 43. Again, Appellants support their claim by pointing to the Plan’s treatment of
the Retained Assets—which we have held above was not improper—and insisting
without support that the entire bankruptcy was put forth solely to prevent their
recovery. On appeal, as below, Appellants “ha[ve] not presented anything but
innuendo in support of [their] argument that [Akorn] failed to act in good faith.”
PWS, 228 F.3d at 243. The Bankruptcy Court and District Court’s good faith
determinations were not an abuse of discretion.
V.
For the foregoing reasons, we will affirm the judgment of the District Court.
3 Contrary to Appellants’ assertions, these remedies do not stem from the Standstill Agreement; it states that it is “temporary and limited in nature,” and cannot prevent the Secured Lenders “from exercising any rights” under the loan agreement. JA332. As the District Court pointed out, “Appellants have not identified anything in the standstill agreement that negates the lenders’ rights under the loan agreement.” JA144. 9